tgDCC-E1A injection of E1A tumor suppressor gene: TGEN began U.S. open-label Phase II testing

By WIR Staff | Oct 12, 1998 | 7:00 AM GMT

Targeted Genetics Corp. (TGEN), Seattle, Wash.
Product: tgDCC-E1A injection of

Read the full 108 word article

How to gain access

Continue reading with a
two-week free trial.